Respiratory

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.

A presentation at the 46th National Association of Pediatric Nurse Practitioners (NAPNAP) conference explored the role of biologics in pediatric care, their applications in various conditions, and safety considerations for clinicians.

An overview of commercially available infant cardiorespiratory monitors and pulse oximeters in the home.

Study findings underscore the effectiveness of a dual approach to RSV prevention.

Most children with MIS-C recover within 6 months, with heart function and overall health improving significantly, according to a new study.

M pneumoniae infection is not a reportable disease, and testing is often not performed in the outpatient setting, limiting estimates of clinical prevalence and delaying recognition of community epidemics.

Cyclo Therapeutics has enrolled 10 patients in a single-arm sub-study treating newborns to 3 years of age, evaluating the Trappsol Cyclo in the youngest subsets.

Allergic sensitization was more prominent in severe phenotypes but did not explain seasonal differences.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Can you diagnose this patient?

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the January/February, 2025, issue of Contemporary Pediatrics.

The patient had increased her vape use recently, but did not disclose when she started, or how much she vaped.

Detectable TTE in children's urine were 'significantly higher' in homes with reported in-home cannabis smoking.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The study within a single health care system revealed that most infants born prior to December received the nirsevimab monoclonal antibody.

The federal agency has set a target action date of June 10, 2025 for potential approval.

The halt follows a severe respiratory disease safety signal observed in a July 2024 phase 1 trial of Moderna's mRNA-1345 and mRNA-1365 vaccine candidates.

Zelicapavir demonstrated a favorable safety profile and was well-tolerated. The N-protein inhibitor has been granted Fast Track Designation by the FDA.

Results demonstrated that those with earlier asthma onset had slower development of episodic memory.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19.

The primary endpoint of the study was survival free of BPD at 36 weeks' postmenstrual age.

"The novel RSV prevention strategies may reduce ICU morbidity and mortality for children," the study authors concluded.

Octavio Ramilo, MD, joins us to discuss new clesrovimab phase 2b/3 study data presented at IDWeek 2024 in Los Angeles, California.

There were no treatment or RSV-related deaths during the study.